Clinical Trial Update: A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy [Phase 2]

View source ↗

Summary

A Phase 2 trial of CVL-871 in subjects with dementia-related apathy was terminated, with results on safety, tolerability, and pharmacodynamics posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia

Drugs mentioned

• CVL-871

Snippet

Sponsor: AbbVie | Conditions: Apathy in Dementia | Phase 2 | Status: TERMINATED | Results posted: 2026-03-11